X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.globenewswire.com/news-release/2024/04/25/2869573/0/en/Compass-Therapeutics-Receives-FDA-Fast-Track-Designation-for-the-Investigation-of-CTX-009-in-Combination-with-Paclitaxel-for-the-Treatment-of-Patients-with-Metastatic-or-Locally-Ad.html
https://www.ema.europa.eu/en/documents/overview/pazenir-epar-medicine-overview_en.pdf
https://www.gsk.com/en-gb/media/press-releases/jemperli-plus-zejula-combination-significantly-improved-progression-free-survival-in-endometrial-cancer-phase-iii-trial/
https://www.globenewswire.com//news-release/2023/11/17/2782524/0/en/Adlai-Nortye-Announces-Completion-of-Patient-Enrollment-in-Global-Phase-III-Clinical-Trial-of-Buparlisib-AN2025-in-Combination-with-Paclitaxel-for-the-Treatment-of-Recurrent-or-Met.html
https://www.fiercepharma.com/pharma/bristol-myers-beigene-end-legacy-celgene-deal-settlement-years-after-china-ban
https://www.onclive.com/view/pelareorep-plus-paclitaxel-induces-responses-in-metastatic-hr-her2-breast-cancer
https://www.onclive.com/view/intra-arterial-gemcitabine-improves-os-in-locally-advanced-pancreatic-cancer
https://www.globenewswire.com/news-release/2023/06/27/2695267/0/en/Journal-of-Clinical-Oncology-Publishes-Results-of-Corcept-s-Phase-2-Trial-of-Relacorilant-in-Women-With-Platinum-Resistant-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2023/01/19/2592170/0/en/Compass-Therapeutics-Announces-that-the-Phase-2-Data-of-CTX-009-in-Combination-with-Paclitaxel-in-Patients-with-Biliary-Tract-Cancers-BTC-will-be-Presented-at-the-ASCO-GI-Cancers-S.html
https://www.globenewswire.com/news-release/2023/01/19/2591871/37414/en/Panbela-Announces-Adoption-of-Commission-Implementing-Decision-from-the-EMA-for-the-Orphan-Designation-of-Ivospemin-SBP-101-in-Combination-with-Gemcitabine-and-Nab-Paclitaxel-in-Pa.html
https://www.globenewswire.com/news-release/2022/12/20/2577055/0/en/Athenex-Announces-Quantum-Leap-Healthcare-Collaborative-Reports-Positive-Trial-Result-of-I-SPY2-Trial-for-Oral-Paclitaxel-in-Combination-with-PD-1-and-Carboplatin-in-Neoadjuvant-Br.html
https://www.globenewswire.com/news-release/2022/12/14/2573721/37414/en/Panbela-Receives-Positive-EMA-Opinion-on-Orphan-Designation-for-Ivospemin-SBP-101-in-Combination-with-Gemcitabine-and-Nab-Paclitaxel-in-Patients-with-Metastatic-Pancreatic-Ductal-A.html
https://www.prnewswire.com/news-releases/dragonfly-therapeutics-initiates-phase-2-study-of-her2-targeting-trinket-df1001-in-patients-with-advanced-solid-tumors-301695342.html
https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-ruby-phase-iii-trial-met-its-primary-endpoint-in-a-planned-interim-analysis-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer/
https://www.globenewswire.com/news-release/2022/11/14/2554776/29489/en/AIM-ImmunoTech-Announces-Presentation-of-New-Data-from-Roswell-Park-Comprehensive-Cancer-Center-Evaluating-Ampligen-as-a-Component-of-a-Chemokine-Modulating-CKM-Regimen-with-Paclit.html
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/abraxis-bioscience-llc-633713-10312022
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-for-generic-injection-to-treat-cancer/articleshow/95115645.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216874
https://www.globenewswire.com/news-release/2022/09/29/2525257/37414/en/Panbela-Receives-Approvals-to-Open-Trial-Sites-in-Spain-France-and-Italy-for-ASPIRE-Trial-Studying-Ivospemin-SBP-101-in-Combination-with-Gemcitabine-and-Nab-Paclitaxel-in-Patients-.html
https://www.globenewswire.com/news-release/2022/09/13/2515521/35057/en/NGM-Bio-Presents-Updated-Preliminary-Findings-from-the-Ongoing-Phase-1b-Dose-Escalation-Trial-of-NGM120-in-Combination-with-Gemcitabine-and-Nab-paclitaxel-in-Patients-with-Metastat.html
https://www.globenewswire.com/news-release/2022/08/11/2496832/37414/en/Panbela-Announces-First-Patient-Enrolled-in-its-Aspire-Trial-Studying-SBP-101-in-Combination-with-Gemcitabine-and-Nab-Paclitaxel-in-Patients-with-Metastatic-Pancreatic-Ductal-Adeno.html
https://www.globenewswire.com/news-release/2022/07/25/2485197/0/en/Athenex-Announces-Publication-of-Data-from-Phase-3-Study-Comparing-Oral-Paclitaxel-Plus-Encequidar-Versus-Intravenous-Paclitaxel-in-Patients-with-Metastatic-Breast-Cancer-in-the-Jo.html
https://www.prnewswire.com/news-releases/innovent-and-lilly-jointly-announce-the-approval-of-tyvyt-sintilimab-injection-by-china-nmpa-in-combination-with-chemotherapy-as-first-line-treatment-for-esophageal-squamous-cell-carcinoma-301570972.html
https://www.globenewswire.com/news-release/2022/06/06/2456669/0/en/Corcept-Therapeutics-to-Start-Phase-3-Trial-of-Relacorilant-Plus-Nab-Paclitaxel-in-Patients-With-Platinum-Resistant-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2022/05/16/2444016/0/en/Junshi-Biosciences-Receives-NMPA-Approval-of-sNDA-for-Toripalimab-in-Combination-with-Paclitaxel-and-Cisplatin-in-First-Line-Treatment-of-Advanced-or-Distant-Metastatic-Esophageal-.html
https://www.globenewswire.com/news-release/2022/05/04/2435529/0/en/Compass-Therapeutics-Reports-Positive-Interim-Phase-2-Data-of-CTX-009-in-Combination-with-Paclitaxel-in-Biliary-Tract-Cancers.html
https://www.forbes.com/sites/greatspeculations/2022/04/28/what-to-expect-from-bristol-myers-squibb-stock-after-q1-results/?sh=1516cc674893
https://www.globenewswire.com/news-release/2022/03/30/2413251/0/en/Relacorilant-Plus-Nab-Paclitaxel-Extends-Survival-in-Women-with-Recurrent-Platinum-resistant-Ovarian-Cancer.html
https://www.prnewswire.com/news-releases/oncolytics-biotech-partner-adlai-nortye-advances-chinese-bridging-trial-of-pelareorep-paclitaxel-combination-treatment-in-breast-cancer-to-final-dosing-cohort-301509468.html
http://www.pharmafile.com/news/610883/nice-draft-guidance-does-not-recommend-pembrolizumab-plus-chemo-triple-negative-breast-c
https://www.prnewswire.com/news-releases/well-begun-and-half-done--sirona-randomized-trial-achieves-fifty-percent-enrollment-301478763.html
https://endpts.com/microcap-cancer-player-goes-belly-up-after-pancreatic-tumor-hopeful-flops-key-study/
https://www.globenewswire.com/news-release/2022/01/26/2373559/37414/en/Panbela-Initiates-a-Randomized-Double-Blind-Placebo-Controlled-Study-ASPIRE-of-Nab-Paclitaxel-and-Gemcitabine-With-or-Without-SBP-101-in-Subjects-Previously-Untreated-for-Metastati.html
https://www.globenewswire.com/news-release/2022/01/24/2371765/37414/en/Panbela-Presents-Clinical-Data-on-Phase-1b-Clinical-Trial-of-SBP-101-in-Combination-with-Gemcitabine-and-Nab-Paclitaxel-in-Patients-with-Metastatic-PDA-at-2022-ASCO-GI-Meeting.html
https://trialsitenews.com/pieris-pharmaceuticals-announces-first-patient-dosed-phase-2-gastric-cancer-trial-evaluating-4-1bb-her2-bispecific-cinrebafusp-alfa/
https://www.marketwatch.com/story/erytech-pharma-shares-fall-after-disappointing-pancreatic-cancer-trial-271635158039
https://www.fiercebiotech.com/biotech/gilead-s-immunomedics-cmo-jumps-to-aadi-as-biotech-looks-for-first-fda-approval-next-month
https://www.globenewswire.com/news-release/2021/10/23/2319430/0/en/OncXerna-Therapeutics-Announces-New-Biomarker-Data-from-Retrospective-Analysis-of-Results-from-Phase-1b-Ovarian-Cancer-Trial-of-Navicixizumab-Plus-Paclitaxel-at-the-ESGO-2021-Congr.html
https://endpts.com/some-cancer-patients-now-have-to-find-other-options-as-bristol-myers-abraxane-falls-into-shortage-from-manufacturing-woes/
https://www.fiercepharma.com/manufacturing/cancer-rivalry-sours-pharma-relationship-bristol-myers-nixes-beigene-s-abraxane-deal
https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-takeda-s-cell-gene-therapy-deals-bms-beigene-abraxane-brawl
https://www.prnewswire.com/news-releases/oncolytics-biotechpartner-adlai-nortye-doses-first-patient-in-chinese-bridging-trial-evaluating-pelareorep-paclitaxel-combination-treatment-in-breast-cancer-301400289.html
Market Place
Share 
